Accueil   Diary - News   All news iDD Biotech : second milestone payment from Genmab for GEN1029 safety trial

iDD Biotech : second milestone payment from Genmab for GEN1029 safety trial

iDD Biotech receives second milestone payment from Genmab with enrolment of fifth patient in GEN1029 (Hexabody®-DR5/DR) safety trial
in patients with malignant solid tumors


Lyon, France – December 4, 2018 –iDD biotech, a French immuno-oncology company with a large pipeline of preclinical and clinical stage monoclonal antibodies, reports that it has received a second milestone payment after its partner, Genmab, started a Phase I/IIa trial of GEN1029 (HexaBody-DR5/DR5). This potent and innovative combination of two anti-DR5 antibodies was discovered and developed by iDD biotech, who established preclinical proof of concept in solid tumors with unmet medical needs.

 

Read the press release